Search tips
Search criteria 


Logo of jidLink to Publisher's site
J Infect Dis. 2011 August 15; 204(4): 495–498.
PMCID: PMC3144171
Editor's Choice

Viral Kinetics of Genital Herpes: A Molecular Probe Into Host-Viral Interactions

(See the article by Schiffer et al, on pages 554–561.)

Utilization of new technological advances in molecular biology have enabled investigators to accurately measure the quantitative amount of viral nucleic acids produced within a host over time, thereby enabling investigations into host-viral interactions. The initial development and use of quantitative viral load assays for human immunodeficiency virus type 1 (HIV-1) provided key insights into the kinetics and pathogenesis of viral replication, host immune responses responsible for the initial decline in viral replication, the establishment of viral set points, and clinical correlates associated with the natural history of HIV-1 infection [17]. Similarly, the effectiveness of antiretroviral therapy was first measured in humans by assessing the impact of these drugs on HIV-1 viral kinetics [810]. Viral kinetic studies have also elucidated our understanding of host-viral interactions in influenza A, hepatitis B and C, and Epstein-Barr virus and cytomegalovirus infections [1115]. These detailed quantitative viral studies have enabled investigators to examine the efficacy of antiviral compounds in limiting viral replication while assessing the development of resistance with resurgence in viral replication. Viral kinetic studies have also provided a deeper understanding of the natural history of viral infections in humans with establishment of latent reservoirs, viral shedding, and viral clearance [1620]. In addition, studies on viral load have shed light on the probability of viral transmission from mother to infant [21, 22] and sexual transmission from one person to another [23, 24]. More recently, these viral kinetic studies have stimulated a newly emerging field regarding the effectiveness of antiviral agents on viral replication as a surrogate in modeling their population transmission effects. For example, reductions in HIV-1 loads in a community as a consequence of scaling up treatment are being found to be associated with subsequent reductions in HIV-1 transmission and incidence [25].

In this issue of the Journal, Schiffer and colleagues [26] apply this same molecular technology to carefully dissect the viral kinetics of mucosal herpes simplex virus type 2 (HSV-2) infection in immunocompetent individuals. Their studies provide a unique insight into the viral replication capacity of HSV-2 and the subsequent host immune reactions to the virus responsible for limiting viral shedding. Genital herpes is an extremely common infection that establishes latency in nerve root ganglia for the life of an infected individual. More than 50 million people in the United States are estimated to be infected, and serologic surveys for HSV-2 estimate that 16.2% of 14–49-year-old individuals in the United States are infected [27, 28]. In 2009, >300000 individuals sought medical care for genital herpes, a steady increase in comparison with previous years [27]. Worldwide, the frequency of infection is even higher, with prevalence rates of HSV-2 infection in Africa, Latin America, and Asia of 30%–60% in similarly aged groups [29]. This high frequency of infection within such diverse populations suggests rather high efficiency in sexual transmission.

Genital herpes includes an initial infection that lasts several weeks followed by recurrent episodes of viral shedding, which are highly variable in frequency, and signs and symptoms. More than 80% of seropositive individuals are unaware of any signs or symptoms consistent with genital herpes [3032]. However, nearly all seropositive individuals, regardless of symptoms, will intermittently shed herpes virus from dermatologic or mucosal sites [3336]. Symptomatic individuals develop recurrences that are characterized by painful, small genital ulcers that usually resolve promptly within a week in immunocompetent individuals, only to recur intermittently over a subsequent period that varies among individuals. In asymptomatic individuals, serial sampling demonstrates shedding of HSV-2 DNA in intermittent bursts of replication at frequent intervals both during and between recurrences [3335]. Previous detailed studies have documented the high frequency of viral shedding, which lasts for very brief periods (hours to days) [3338]. It is this unpredictable intermittent shedding of HSV-2 that is responsible for subsequent transmission to sexual partners and that poses a continual threat of perinatal transmission [30, 31, 39, 40].

Although it has been postulated that the higher frequency of shedding is most likely associated with greater probabilities of transmission, the actual quantitative level of viral replication associated with these shedding episodes had not been thoroughly documented. Little is known about how much virus is produced locally at these genital sites either during or between episodes of recurrence, how long the shedding lasts, and what the characteristics of the host immune response are that limit these viral kinetics. Schiffer et al [26] addressed several of these questions by quantifying the amount of HSV-2 shedding on a daily basis in 531 immunocompetent HSV-2–seropositive persons. They systematically collected >14600 genital swabs over several years. By measuring the quantity of virus in these swabs, the investigators were able to fully document the duration, peak copy number, and expansion and decay rates of HSV-2 in >1800 symptomatic and asymptomatic viral shedding episodes. This is the first study to document quantitatively the amount of virus actively being produced and shed locally during these recurrent herpetic episodes.

Consistent with the results of previous studies on shedding frequency, Schiffer et al [26] found significant heterogeneity in the duration of episodic viral shedding, with a median duration of 3 days and with slightly more than one-quarter of episodes lasting only 1 day and 20% lasting >9 days. Similarly, there was a wide range of peak genomic production levels, with a positive association between episode duration and peak copy number. The investigators were also able to calculate an extremely rapid expansion rate of viral replication of 7.5 log copies/mL of viral DNA produced during the first 12 hours of an episode. Because only 1 swab was collected per 24 hours, it remained uncertain as to whether the rate of replication was constant, whether there was a single burst of viral replication, or whether it was slower during the initial hours of the episode with a subsequent burst after HSV-2 DNA copy numbers surpassed 103 copies/mL. Only more frequent sampling just before and during an episode will enable us to address the initial kinetics of viral replication.

Following this initial burst of replication, the host’s immune response is rapidly activated and limits viral production, producing a unimodal curve in the majority of people sampled. Schiffer et al [26] calculated that the average rate of viral decay following the peak viral replication was −6.2 log copies/mL of viral DNA during the final 12 hours of the episode, ultimately resulting in final termination of each episode. However, as with all biological responses to infection, there is heterogeneity in the observed responses to herpes virus production. One-fifth of the subjects with a detectable viral level demonstrated a nonmonotonic decrease, in which there were intermittent episodes of viral replication interspersed within the viral decay curves, resulting in biphasic or multiphasic decays. This observation was more characteristic of individuals who had prolonged episodes of >7 days. These nonmonotonic decreases in viral replication levels suggest that the host immune response was only partially effective in its initial response, but improved over time to finally suppress viral replication. Similar variability within viral kinetics was observed in those individuals who developed genital ulcers (higher peak viral copy numbers and prolonged decay), compared with those who remained asymptomatic. These findings also suggest that the host’s ability to limit viral replication may directly influence the clinical variability observed in infections in humans.

These observed viral dynamics provided additional support for a model of viral-host immune interactions previously postulated by these investigators based on the frequency of viral shedding [30, 4143]. Following primary infection, viral latency is established in the sacral ganglia. Viral reactivation in the ganglia may be self-limited, but it results in centrifugal migration of HSV-2 along sensory nerves. Subsequent viral release from the sensory neurons into the genital tract leads to subclinical shedding of virus or development of a herpetic lesion with even higher viral production. These prolonged episodes are associated with higher peak copy numbers and, consequently, higher inocula at time of coitus, which correlates with the higher probability of transmission.

The enormous amount of viral replication stimulates a host immune response that is characterized by infiltration of the dermis with both CD4+ and CD8+ lymphocytes [44]. This response appears to be critical in the clearance of a genital lesion and ultimately leads to cessation of viral shedding. Serial biopsies of genital sites and examination of excised foreskins from HSV-2–seropositive individuals demonstrate persistence of specific immune CD4+ and CD8+ T cells for months at the dermal-epidermal junction where HSV-2 is released from the neurons [4446]. It is, therefore, likely that the persistence and subsequent activation of these immune cells during viral replication is ultimately responsible for the very rapid clearance of the virus from these sites. The high frequency of viral shedding may contribute to the persistence of these immune cells locally. Thus, the response to intermittent episodes of peak viral production is likely to be dependent on the density and effectiveness of HSV-2 immune primed CD8+ lymphocytes.

Although the study by Schiffer et al [26] provides insight into HSV-2 viral kinetics in immunocompetent individuals, it raises the specter of how an immunocompromised host would alter HSV-2 viral kinetics. HIV-1/HSV-2 dually infected individuals are known to have greater persistence of genital ulcers, and it is likely that peak viral production at genital sites will be much higher and prolonged due to slower decay rates than that observed in this study, thereby complicating the healing of any ulcers and enhancing the transmission of both viruses [4749]. Another question raised by this study is what the effect of antivirals will be on the peak and duration of viral replication. Although HSV-2 antivirals are effective in suppressing clinical episodes and partially limiting episodes of shedding, they are only partially effective in preventing sexual transmission [39], once again emphasizing the importance of a very effective immune response in addition to therapy. Finally, these studies raise the question of what host or viral signals activate virus replication, and why and when they occur. What role do cytokines actively play in promoting activation or cessation of virus production? These questions are clinically important and might translate ultimately into a better understanding of this viral infection, leading to better therapy, prevention in transmission, and development of an effective vaccine.


This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.


The author wishes to thank Aaron Tobian for his helpful comments and critique in preparation of this editorial.


1. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123–6. [PubMed]
2. Riddler SA, Mellors JW. HIV-1 viral load and clinical outcome: review of recent studies. AIDS. 1997;11(suppl A):S141–8. [PubMed]
3. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946–54. [PubMed]
4. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis. 2000;181:872–80. [PubMed]
5. Gange SJ, Mellors JW, Lau B, et al. Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. AIDS Res Hum Retroviruses. 2001;17:1223–9. [PubMed]
6. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. The relationship between initial HIV-1 RNA level after seroconversion and progression to AIDS in women and men: implications for initiation of antiretroviral therapy. N Engl J Med. 2001;344:720–5. [PubMed]
7. Gray RH, Li X, Wawer M, et al. Determinants of HIV-1 viral load with incident and prevalent infections in a general population of Rakai, Uganda. J Infect Dis. 2004;189:1209–15. [PubMed]
8. Perelson A, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–91. [PubMed]
9. Huang W, De Gruttola V, Fischl M, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis. 2001;183:1455–65. [PubMed]
10. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879–4. [PubMed]
11. Ribeiro RM, Lo A, Perelson AS. Dynamics of hepatitis B virus infection. Microbes Infect. 2002;4:829–35. [PubMed]
12. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103–7. [PubMed]
13. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol. 2006;80:7590–9. [PMC free article] [PubMed]
14. Hadimoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog. 2009;5:e1000496. [PMC free article] [PubMed]
15. Jabs DA, Gilpin AM, Min YI, Erice A, Kempen JH, Quinn TC. Studies of Ocular Complications of AIDS Research Group. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS. 2002;16:877–87. [PubMed]
16. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–300. [PubMed]
17. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–8. [PubMed]
18. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–8. [PubMed]
19. Perelson A, Neumann A, Markowitz M, Leonard J, Ho D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582–6. [PubMed]
20. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009;106:9403–8. [PubMed]
21. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394–402. [PubMed]
22. Thomas DL, Villano SA, Riester KA, et al. Association of high viral load with perinatal transmission of hepatitis C virus: a study of mothers infected with human immunodeficiency virus. J Infect Dis. 1998;177:1480–8. [PubMed]
23. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and the risk of heterosexual transmission of human immunodeficiency virus type 1 among sexual partners. N Engl J Med. 2000;342:921–9. [PubMed]
24. Hollingsworth TD, Laeyendecker O, Shirreff G, et al. HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog. 2010;6:e1000876. [PMC free article] [PubMed]
25. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068. [PMC free article] [PubMed]
26. Schiffer JT, Wald A, Selke S, Corey L, Magaret A. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis. 2011;204:554–61. [PMC free article] [PubMed]
27. Sexually transmitted disease surveillance 2009. Centers for Disease Control and Prevention. 2010 Accessed 1 December 2010.
28. Centers for Disease Control and Prevention (CDC) Seroprevalence of herpes simplex virus type 2 among persons aged 14–49 years—United States, 2005–2008. MMWR Morb Mortal Wkly Rep. 2010;59:456–9. [PubMed]
29. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86:805–12. [PubMed]
30. Schiffer JT, Corey L. New concepts in understanding genital herpes. Curr Infect Dis Rep. 2009;11:457–64. [PMC free article] [PubMed]
31. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis. 2008;198:1098–100. [PubMed]
32. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med. 2008;59:381–95. [PubMed]
33. Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis. 2011;203:180–7. [PMC free article] [PubMed]
34. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr. 2010;54:482–8. [PMC free article] [PubMed]
35. Fife KH, Williams JA, Thomas AL, Ofner S, Katz BP, Fortenberry JD. Herpes simplex virus type 2 infection in young adult women: risk factors for infection and frequency of viral shedding. Sex Transm Dis. 2010;37:248–52. [PubMed]
36. Tata S, Johnston C, Huang ML, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis. 2010;201:499–504. [PMC free article] [PubMed]
37. Magaret AS, Johnston C, Wald A. Use of the designation “shedder” in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect. 2009;85:270–5. [PMC free article] [PubMed]
38. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198:1141–9. [PMC free article] [PubMed]
39. Kim HN, Wald A, Harris J, Almekinder J, Heitman C, Corey L. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Sex Transm Dis. 2008;35:124–8. [PubMed]
40. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342:844–50. [PubMed]
41. Schiffer JT, Abu-Raddad L, Mark KE, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010;107:18973–8. [PubMed]
42. Schiffer JT, Abu-Raddad L, Mark KE, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2009;1:1–9. [PMC free article] [PubMed]
43. Crespi CM, Cumberland WG, Wald A, Corey L, Blower S. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect. 2007;83:359–64. [PMC free article] [PubMed]
44. Zhu J, Koelle D, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007;204:595–603. [PMC free article] [PubMed]
45. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009;15:886–92. [PMC free article] [PubMed]
46. Johnson KE, Redd AD, Quinn TC, et al. Effects of HIV-1 and HSV type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda. J Infect Dis. 2011;203:602–9. [PMC free article] [PubMed]
47. Tobian AA, Quinn TC. Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS. 2009;4:294–9. [PMC free article] [PubMed]
48. Corey L, Wald A, Celum C, Quinn TC. The effects of HSV-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435–45. [PubMed]
49. Serwadda D, Gray RH, Sewnkambo NK, et al. HIV acquisition associated with genital ulcer disease and herpes simplex type 2: what is cause and what is effect? A nested case-control study in Rakai, Uganda. J Infect Dis. 2003;188:1492–7. [PubMed]

Articles from The Journal of Infectious Diseases are provided here courtesy of Oxford University Press